.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,968,551

« Back to Dashboard

Claims for Patent: 5,968,551

Title: Orally administrable opioid formulations having extended duration of effect
Abstract:Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.
Inventor(s): Oshlack; Benjamin (New York, NY), Chasin; Mark (Manalapan, NJ)
Assignee: Purdue Pharma L.P. (Norwalk, CT)
Application Number:08/508,246
Patent Claims: 1. A bioavailable sustained-release oral analgesic dosage form for once-a-day administration, comprising:

a unit dose comprising a plurality of pharmaceutically acceptable matrices comprising an analgesically effective amount of an opioid analgesic or a salt thereof and a hydrophobic material, each of said matrices having a diameter from about 0.1 mm to about 3 mm, said dosage form being bioavailable and providing a therapeutic effect for about 24 hours or more after oral administration to a human patient.

2. The dosage form of claim 1, wherein said matrices are selected from the group consisting of spheroids, pellets, ion-exchange resin beads, granules, and mixtures thereof.

3. A method for preparing a bioavailable sustained-release opioid analgesic dosage form for once-a-day oral administration, comprising preparing a unit dose comprising a plurality of inert beads coated with an opioid analgesic or a salt thereof and a sustained-release coating comprising a hydrophobic material, such that each of said beads has a diameter from about 0.1 to about 3 mm and such that said dosage form provides an in-vitro dissolution indicative of a once-a-day oral dosage form, is bioavailable, and provides a therapeutic effect for about 24 hours or more after oral administration to a human patient.

4. The dosage form of claim 1 wherein said matrices comprise a substantially uniform mixture of said opioid analgesic or salt thereof and said hydrophobic material.

5. The dosage form of claim 1, wherein said opioid analgesic is selected form the group consisting of morphine, codeine, hydromorphone, hydrocodone, oxycodone, oxymorphone, dihydrocodeine, dihydromorphine, and mixtures thereof.

6. The dosage form of claim 1, wherein said opioid analgesic is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof and mixtures thereof.

7. The dosage form of claim 1, wherein said opioid analgesic or salt thereof consists of from about 2 mg to about 64 mg hydromorphone.

8. The dosage form of claim 1, wherein said opioid analgesic or salt thereof consists of from about 5 mg to about 800 mg morphine.

9. The dosage form of claim 1, wherein said opioid analgesic or salt thereof consists of from about 5 mg to about 400 mg oxycodone.

10. The method of claim 3, further comprising incorporating said unit dose within a hard gelatin capsule.

11. A bioavailable sustained-release dosage form for once-a-day oral administration of morphine, comprising

a unit dose of inert pharmaceutically acceptable beads having a diameter from about 0.1 mm to about 3 mm coated with an analgesically effective amount of morphine or a salt thereof, said beads further comprising a sustained-release overcoat comprising an effective amount of a hydrophobic material selected from an acrylic polymer, an alkyl cellulose, and mixtures thereof, said unit dose being bioavailable and providing a therapeutic effect for about 24 hours or more after oral administration.

12. The dosage form of claim 1, wherein said hydrophobic material is selected from the group consisting of an acrylic polymer, an alkylcellulose, shellac, zein, hydrogenated vegetable oil, hydrogenated castor oil, and mixtures of any of the foregoing.

13. The method of claim 3, further comprising incorporating a therapeutically effective amount of a non-opioid drug into said unit dose.

14. The dosage form of claim 1, wherein said matrices are contained in a hard gelatin capsule.

15. The dosage form of claim 1, wherein each of said matrices has a diameter of from about 0.5 mm to about 2 mm.

16. The dosage form of claim 3, wherein each of said beads is from about a 8 mesh bead to about 50 mesh bead.

17. The dosage form of claim 1, further comprising a release-modifying agent.

18. The dosage form of claim 1, further comprising a non-opioid drug.

19. The dosage form of claim 18, wherein the said non-opioid drug is a non-steroidal anti-inflammatory agent.

20. The dosage form of claim 19, wherein said non-steroidal anti-inflammatory agent is selected from the group consisting of ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, and mixtures of any of the foregoing.

21. A bioavailable sustained-release opioid analgesic dosage form for once-a-day oral administration, consisting essentially of

a unit dose of inert pharmaceutically acceptable beads coated with an analgesically effective amount of an opioid analgesic or a salt thereof, said beads further comprising a sustained-release overcoat comprising an effective amount of a hydrophobic material selected from the group consisting of an acrylic polymer, an alkylcellulose, shellac, zein, hydrogenated vegetable oil, hydrogenated castor oil, and mixtures of any of the foregoing, and said coated beads having a diameter from about 0.1 mm to about 3 mm, said dosage form being bioavailable and providing a therapeutic effect for about 24 hours or more after oral administration to a human patient.

22. The dosage form of claim 21, wherein said opioid analgesic or salt thereof consists of from about 2 mg to about 64 mg hydromorphone.

23. The dosage form of claim 21, wherein said opioid analgesic or salt thereof consists of from about 5 mg to about 800 mg morphine.

24. The dosage form of claim 21, wherein said opioid analgesic or salt thereof consists of from about 5 mg to about 400 mg oxycodone.

25. The method of claim 13, wherein the said non-opioid drug is a non-steroidal anti-inflammatory agent.

26. The dosage form of claim 21, wherein said unit dose of said beads are contained within a hard gelatin capsule.

27. The dosage form of claim 21, wherein each of said beads has a diameter from about 0.5 to about 2 mm.

28. The dosage form of claim 21, wherein each of said beads is from about 8 mesh to about 50 mesh.

29. The dosage form of claim 21, wherein said opioid analgesic is selected form the group consisting of morphine, codeine, hydromorphone, hydrocodone, oxycodone, oxymorphone, dihydrocodeine, dihydromorphine, and mixtures thereof.

30. A dosage form of claim 29, further comprising a non-opioid drug.

31. The dosage form of claim 30, wherein the said non-opioid drug is a non-steroidal anti-inflammatory agent.

32. The dosage form of claim 31, wherein said non-steroidal anti-inflammatory agent is selected from the group consisting of ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, and mixtures of any of the foregoing.

33. A method of treating a patient for moderate to severe pain with a bioavailable sustained-release opioid analgesic dosage form for once-a-day oral administration, comprising orally administering to a patient on a once-a-day basis a unit dose of an oral opioid analgesic consisting essentially of a plurality of inert pharmaceutically acceptable beads coated with an analgesically effective amount of an opioid analgesic or a salt thereof and overcoated with a hydrophobic material, such that each of said heads has a diameter from about 0.1 mm to about 3 mm, said unit dose being bioavailable and manufactured in a sustained-release form to provide therapeutically effective blood plasma levels of said opioid analgesic for about 24 hours or more.

34. The method of claim 33, further said unit dose is prepared by coating said inert pharmaceutically acceptable beads with said opioid analgesic, and thereafter overcoating with a hydrophobic material selected from the group consisting of an acrylic polymer, an alkyl cellulose, shellac, zein, hydrogenated vegetable oil, hydrogenated castor oil, and mixtures of any of the foregoing.

35. The method of claim 33, further comprising incorporating a therapeutically effective amount of a non-steroidal anti-inflammatory agent into said unit dose.

36. The method of claim 33, further comprising preparing said coated beads such that said unit dose provides a peak plasma level of said opioid in-vivo from about 3 to about 10 hours after administration.

37. The method of claim 33, further comprising preparing said coated beads such that said unit dose provides a peak plasma level of said opioid in-vivo from about 2 to about 4 hours after administration.

38. The method of claim 33, further comprising incorporating said unit dose within a hard gelatin capsule.

39. The dosage form of claim 18, wherein said non-opioid drug is selected from the group consisting of acetaminophen and aspirin.

40. The dosage form of claim 30, wherein said non-opioid drug is selected from the group consisting of acetaminophen and aspirin.

41. The method of claim 13, wherein said non-opioid drug is selected from the group consisting of acetaminophen and aspirin.

42. The method of claim 33, further comprising incorporating a therapeutically effective amount of aspirin or acetaminophen into said unit dose.

43. The dosage form of claim 17, wherein said release modifying agent comprises a hydrophilic polymer.

44. The dosage form of claim 43, wherein said hydrophilic polymer comprises hydroxypropylmethylcellulose.

45. The method of claim 3, wherein said opioid analgesic is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof and mixtures thereof.

46. A bioavailable sustained-release opioid analgesic dosage form for once-a-day oral administration, comprising

inert pharmaceutically acceptable beads having a diameter from about 0.1 mm to about 3 mm coated with an analgesically effective amount of an opioid analgesic or a salt thereof, said beads further comprising a sustained-release overcoat comprising an effective amount of a hydrophobic material in an amount sufficient to provide a sustained-release of said opioid analgesic such that said dosage form provides a therepeutic effect for about 24 hours or more after oral administration to a human patient.

47. The dosage form of claim 46, wherein said opioid analgesic or salt thereof consists of from about 2 mg to about 64 mg hydromorphone.

48. The dosage form of claim 46, wherein said opioid analgesic or salt thereof consists of from about 5 mg to about 800 mg morphine.

49. The dosage form of claim 46, wherein said opioid analgesic or salt thereof consists of from about 5 mg to about 400 mg oxycodone.

50. The dosage form of claim 46, wherein said hydrophobic material is selected from the group consisting of an acrylic polymer, an alkyl cellulose, and mixtures thereof.

51. The dosage form of claim 46, wherein said opioid analgesic is morphine sulfate and said hydrophobic material is selected from the group consisting of an acrylic polymer, an alkyl cellulose, and mixtures thereof.

52. The method of claim 25, wherein said non-steroidal anti-inflammatory drug is selected from the group consisting of ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, and mixtures of any of the foregoing.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc